Noordhof AL, Damhuis RAM, Hendriks LEL, de Langen AJ, et al. Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. Lung Cancer 2021;155:163-169.
PMID: 33838467